Gilead to present 28 abstracts on HIV treatment, prevention and emerging antiviral research at IDWeek 2026

Gilead Sciences will present new findings from its HIV and antiviral research programmes at IDWeek 2026, held from 21 to 24 October in Washington, D.C. The company will give 28 presentations, two of them oral, covering HIV treatment, HIV prevention, the wider experiences of people living with HIV, and emerging antiviral programmes. The Phase 1b data for investigational GS-1179 will focus on virologic efficacy, safety and tolerability in recurrent genital herpes.

Jared Baeten, MD, PhD, senior vice president of clinical development and virology therapeutic area head at Gilead, said the company remains committed to advancing options for people affected by HIV and other serious diseases, as the breadth of its research and antiviral pipeline shows. He said the findings span clinical research and real world evidence, deepening understanding of changing needs and informing innovations that could make a meaningful difference to the communities Gilead serves.

HIV treatment research

New analyses from the Phase 3 ARTISTRY-1 and ARTISTRY-2 studies will give further insight into the safety and efficacy of Bixlenvo™ (bictegravir 75 mg/lenacapavir 50 mg). It is the smallest once daily single tablet regimen for adults with HIV who are virologically suppressed, including those on complex regimens. New ARTISTRY-1 sub-analyses will look at outcomes in participants with comorbidities such as dyslipidaemia, hypertension, diabetes mellitus and renal impairment, building on data from the oldest study population in a Phase 3 registrational HIV-1 treatment trial to date. ARTISTRY-2 findings will examine metabolic and safety outcomes in people with HIV who had selected comorbidities at baseline.

Other treatment research will explore virologic effectiveness, resistance and strategies for restarting antiretroviral therapy after interruptions in care. This includes studies in historically under-resourced communities and analyses of real world treatment patterns. Data from the Phase 4 ACCELERATE Implementation Study will also be presented on Biktarvy® (bictegravir/emtricitabine/tenofovir alafenamide), looking at rapid antiretroviral therapy restart for people with HIV who return to care.

HIV prevention research

Gilead will present research on early real world adoption of twice yearly Yeztugo® (lenacapavir) for HIV pre-exposure prophylaxis in the United States during the first nine months after FDA approval. Yeztugo is the only FDA approved twice yearly option for people who need or want PrEP. Further studies will look at what shapes PrEP access, uptake and implementation, including provider education, linkage to prevention services, cost sharing, and the potential economic and public health impact of wider HIV prevention.

---

---

Related Topics and Keywords

Antiviral, biktarvy, Biopharma, biopharma news, Bixlenvo, Genital Herpes, gilead, Gilead Sciences, GS-1179, HIV, hiv prevention, HIV Treatment, IDWeek 2026, lenacapavir, Yeztugo